Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

C5874

Sigma-Aldrich

Cidofovir hydrate

≥98% (HPLC), powder, viral DNA synthesis inhibitor

Synonym(s):

(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, (S)-HPMPC; Cidovir, HPMPC, Vistide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C8H14N3O6P · xH2O
CAS Number:
113852-37-2
Molecular Weight:
279.19 (anhydrous basis)
MDL number:
MFCD17215968
UNSPSC Code:
12352200
PubChem Substance ID:
329775105
NACRES:
NA.77

Product Name

Cidofovir hydrate, ≥98% (HPLC)

Quality Level

100

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated
protect from light

solubility

deionized water: ≥5 mg/mL (warmed)

storage temp.

room temp

SMILES string

O.NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1

InChI

1S/C8H14N3O6P.H2O/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16;/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16);1H2/t6-;/m0./s1

InChI key

KLJYJZIIJLYJNN-RGMNGODLSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Selective inhibitor of viral DNA synthesis through the selective inhibition of viral DNA polymerase.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301,H315

Hazard Classifications

Acute Tox. 3 Oral - Skin Irrit. 2

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

C5874-50MG:
C5874-BULK:
C5874-10MG:
C5874-VAR:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
125M4729V
084M4721V
022M4713V
020M47151
020M4715

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ryan N Jennings et al.
Journal of virology, 88(24), 14040-14049 (2014-09-26)
CD8(+) T cell responses are critical to the control of replication and reactivation associated with gammaherpesvirus infection. Type I interferons (IFNs) have been shown to have direct and indirect roles in supporting CD8(+) T cell development and function during viral
Jonathan Schelfhout et al.
Current medical research and opinion, 36(1), 43-50 (2019-09-07)
Objective: This study utilized a large, national US database to explore the impact of Cytomegalovirus (CMV) infection on hospital services utilization and costs during the first 100 days following allogeneic hematopoietic stem cell transplant (allo-HSCT).Methods: This retrospective, observational cohort study used
Joanna Jackowska et al.
Lasers in medical science, 34(7), 1433-1440 (2019-02-15)
Mechanical debulking of laryngeal papillomas is associated with voice disorders due to impairment of the vocal fold's mucosa. Intraepithelial injection of cidofovir reduces damage to the laryngeal structures and thus improves vocal parameters. The aim of our study was to
Successful treatment of perianal giant condyloma acuminatum in an immunocompromised host with systemic interleukin 2 and topical cidofovir.
Vinod E Nambudiri et al.
JAMA dermatology, 149(9), 1068-1070 (2013-07-05)
Stephen D S McCarthy et al.
PLoS neglected tropical diseases, 10(1), e0004364-e0004364 (2016-01-12)
To date there are no approved antiviral drugs for the treatment of Ebola virus disease (EVD). While a number of candidate drugs have shown limited efficacy in vitro and/or in non-human primate studies, differences in experimental methodologies make it difficult
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service